Enrico Iaccino

Dr. Enrico Iaccino

Magna Graecia University of Catanzaro
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
IMIda Manna
Ida Manna
EIEnrico Iaccino
Enrico Iaccino
VDVincenzo Dattilo
Vincenzo Dattilo
SBStefania Barone
Stefania Barone
Eleonora VecchioEleonora Vecchio
Eleonora Vecchio
AQAldo Quattrone
Aldo Quattrone
Multiple sclerosis (MS) is an autoimmune pathology leading to neurodegeneration. Because of the complexity and heterogenic etiology of this disease, diagnosis and treatment for individual patients are challenging. Exosome‐associated microRNAs (miRNAs) have recently emerged as a new class of diagnostic biomarkers involved in both autoimmune and neurologic disorders. Interesting new evidence has emerged showing that circulating miRNAs are dysregulated in MS body fluids, including serum, plasma, and cerebrospinal fluid. We hypothesized that exosome‐associated miRNAs could present a readily accessible blood‐based assay for MS disease. We detected expression of miRNAs by quantitative PCR on a small cohort of MS patients. We analyzed circulating exosome‐associated miRNAs of MS patients before and after therapy and found that 14 exosome‐associated miRNAs were significantly down‐regulated, while 2 exosome‐associated miRNAs were significantly up‐regulated in IFN‐β‐treated relapsing‐remitting MS patients with response to therapy compared to those without response. We identified a serum miRNA panel that could be used to monitor the response to IFN‐β therapy. Overall, these data suggest that circulating exosome‐associated miRNA profiling could represent an easily detectable biomarker of disease and treatment response.—Manna, I., Iaccino, E., Dattilo, V., Barone, S., Vecchio, E., Mimmi, S., Filippelli, E., Demonte, G., Polidoro, S., Granata, A., Scannapieco, S., Quinto, I., Valentino, P., Quattrone, A. Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB J . 32, 4241–4246 (2018). www.fasebj.org

1 February 2019 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SMSelena Mimmi
Selena Mimmi
DMDomenico Maisano
Domenico Maisano
IQIleana Quinto
Ileana Quinto
EIEnrico Iaccino
Enrico Iaccino

1 December 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
IMIda Manna
Ida Manna
AQAldo Quattrone
Aldo Quattrone
SBSelene De Benedittis
Selene De Benedittis
BVBasilio Vescio
Basilio Vescio
EIEnrico Iaccino
Enrico Iaccino
AQAldo Quattrone
Aldo Quattrone

12 September 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
IMIda Manna
Ida Manna
SBSelene De Benedittis
Selene De Benedittis
AQAldo Quattrone
Aldo Quattrone
DMDomenico Maisano
Domenico Maisano
EIEnrico Iaccino
Enrico Iaccino
AQAldo Quattrone
Aldo Quattrone
Alzheimer’s disease (AD), a neurodegenerative disease, is linked to a variety of internal and external factors present from the early stages of the disease. There are several risk factors related to the pathogenesis of AD, among these exosomes and microRNAs (miRNAs) are of particular importance. Exosomes are nanocarriers released from many different cell types, including neuronal cells. Through the transfer of bioactive molecules, they play an important role both in the maintenance of physiological and in pathological conditions. Exosomes could be carriers of potential biomarkers useful for the assessment of disease progression and for therapeutic applications. miRNAs are small noncoding endogenous RNA sequences active in the regulation of protein expression, and alteration of miRNA expression can result in a dysregulation of key genes and pathways that contribute to disease development. Indeed, the involvement of exosomal miRNAs has been highlighted in various neurodegenerative diseases, and this opens the possibility that dysregulated exosomal miRNA profiles may influence AD disease. The advances in exosome-related biomarker detection in AD are summarized. Finally, in this review, we highlight the use of exosomal miRNAs as essential biomarkers in preclinical and clinical studies in Alzheimer’s disease, also taking a look at their potential clinical value.

13 October 2017 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
EIEnrico Iaccino
Enrico Iaccino
SMSelena Mimmi
Selena Mimmi
VDVincenzo Dattilo
Vincenzo Dattilo
FMFabiola Marino
Fabiola Marino
Patrizio CandeloroPatrizio Candeloro
Patrizio Candeloro
GSGiuseppe Scala
Giuseppe Scala
Tumor-derived exosomes (TDEs) play a pivotal role in tumor establishment and progression, and are emerging biomarkers for tumor diagnosis in personalized medicine. To date, there is a lack of efficient technology platforms for exosome isolation and characterization. Multiple myeloma (MM) is an incurable B-cell malignancy due to the rapid development of drug-resistance. MM-released exosomes express the immunoglobulin B-cell receptor (Ig-BCR) of the tumor B-cells, which can be targeted by Idiotype-binding peptides (Id-peptides). In this study, we analyzed the production of MM-released exosomes in the murine 5T33MM multiple myeloma model as biomarkers of tumor growth. To this end, we selected Id-peptides by screening a phage display library using as bait the Ig-BCR expressed by 5T33MM cells. By FACS, the FITC-conjugated Id-peptides detected the MM-released exosomes in the serum of 5T33MM-engrafted mice, levels of which are correlated with tumor progression at an earlier time point compared to serum paraprotein. These results indicate that Id-peptide-based recognition of MM-released exosomes may represent a very sensitive diagnostic approach for clinical evaluation of disease progression.

Verified
Journal Article
Open access
PDF file
SBSelene De Benedittis
Selene De Benedittis
FFFrancesco Fortunato
Francesco Fortunato
CCClaudia Cava
Claudia Cava
FGFrancesca Gallivanone
Francesca Gallivanone
EIEnrico Iaccino
Enrico Iaccino
AGAntonio Gambardella
Antonio Gambardella
MicroRNAs (miRNAs) are small noncoding RNAs that have emerged as new potential epigenetic biomarkers. Here, we evaluate the efficacy of six circulating miRNA previously described in the literature as biomarkers for the diagnosis of temporal lobe epilepsy (TLE) and/or as predictive biomarkers to antiepileptic drug response. We measured the differences in serum miRNA levels by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays in a cohort of 27 patients (14 women and 13 men; mean ± SD age: 43.65 ± 17.07) with TLE compared to 20 healthy controls (HC) matched for sex, age and ethnicity (11 women and 9 men; mean ± SD age: 47.5 ± 9.1). Additionally, patients were classified according to whether they had drug-responsive (n = 17) or drug-resistant (n = 10) TLE. We have investigated any correlations between miRNAs and several electroclinical parameters. Three miRNAs (miR-142, miR-146a, miR-223) were significantly upregulated in patients (expressed as average expression ± SD). In detail, miR-142 expression was 0.40 ± 0.29 vs. 0.16 ± 0.10 in TLE patients compared to HC (t-test, p < 0.01), miR-146a expression was 0.15 ± 0.11 vs. 0.07 ± 0.04 (t-test, p < 0.05), and miR-223 expression was 6.21 ± 3.65 vs. 1.23 ± 0.84 (t-test, p < 0.001). Moreover, results obtained from a logistic regression model showed the good performance of miR-142 and miR-223 in distinguishing drug-sensitive vs. drug-resistant TLE. The results of this pilot study give evidence that miRNAs are suitable targets in TLE and offer the rationale for further confirmation studies in larger epilepsy cohorts.